Leerink Partnrs Issues Optimistic Forecast for TNDM Earnings

Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) - Investment analysts at Leerink Partnrs lifted their Q1 2025 earnings estimates for Tandem Diabetes Care in a report released on Thursday, February 27th. Leerink Partnrs analyst M. Kratky now expects that the medical device company will post earnings per share of ($0.56) for the quarter, up from their previous forecast of ($0.66). The consensus estimate for Tandem Diabetes Care's current full-year earnings is ($1.68) per share. Leerink Partnrs also issued estimates for Tandem Diabetes Care's Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($1.07) EPS, FY2026 earnings at ($0.52) EPS, FY2027 earnings at ($0.08) EPS and FY2028 earnings at $0.31 EPS.

Several other research analysts have also recently commented on the stock. Royal Bank of Canada decreased their target price on shares of Tandem Diabetes Care from $65.00 to $55.00 and set an "outperform" rating for the company in a report on Thursday, February 27th. Robert W. Baird decreased their price target on shares of Tandem Diabetes Care from $37.00 to $33.00 and set a "neutral" rating for the company in a report on Thursday, February 27th. Morgan Stanley cut shares of Tandem Diabetes Care from an "overweight" rating to an "equal weight" rating and decreased their price target for the stock from $45.00 to $22.00 in a report on Wednesday. Citigroup cut shares of Tandem Diabetes Care from a "buy" rating to a "neutral" rating and decreased their price target for the stock from $35.00 to $24.00 in a report on Tuesday. Finally, Wells Fargo & Company restated an "equal weight" rating and set a $22.00 price target (down from $38.00) on shares of Tandem Diabetes Care in a report on Monday. Eight analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat.com, Tandem Diabetes Care currently has a consensus rating of "Moderate Buy" and an average price target of $45.38.

Remove Ads

Tandem Diabetes Care Trading Down 2.0 %

Shares of TNDM traded down $0.39 during midday trading on Monday, hitting $18.72. The stock had a trading volume of 1,713,124 shares, compared to its average volume of 1,480,576. Tandem Diabetes Care has a fifty-two week low of $18.27 and a fifty-two week high of $53.69. The business has a 50-day simple moving average of $33.55 and a two-hundred day simple moving average of $35.75. The firm has a market cap of $1.24 billion, a P/E ratio of -9.70 and a beta of 1.32. The company has a current ratio of 2.90, a quick ratio of 2.32 and a debt-to-equity ratio of 1.29.

Hedge Funds Weigh In On Tandem Diabetes Care

A number of institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its position in shares of Tandem Diabetes Care by 1.1% in the fourth quarter. Vanguard Group Inc. now owns 7,440,005 shares of the medical device company's stock valued at $267,989,000 after purchasing an additional 77,451 shares during the period. ArrowMark Colorado Holdings LLC raised its position in shares of Tandem Diabetes Care by 14.1% in the fourth quarter. ArrowMark Colorado Holdings LLC now owns 2,723,715 shares of the medical device company's stock valued at $98,108,000 after purchasing an additional 337,026 shares during the period. State Street Corp raised its position in shares of Tandem Diabetes Care by 3.2% in the third quarter. State Street Corp now owns 2,655,736 shares of the medical device company's stock valued at $112,630,000 after purchasing an additional 83,172 shares during the period. GW&K Investment Management LLC raised its position in shares of Tandem Diabetes Care by 18.0% in the fourth quarter. GW&K Investment Management LLC now owns 2,123,488 shares of the medical device company's stock valued at $76,488,000 after purchasing an additional 323,674 shares during the period. Finally, Bellevue Group AG raised its position in shares of Tandem Diabetes Care by 19.9% in the third quarter. Bellevue Group AG now owns 1,850,891 shares of the medical device company's stock valued at $78,496,000 after purchasing an additional 307,624 shares during the period.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.